ArticleEpilepsia2025
Association of maternal epilepsy with perinatal outcomes, and an exploration of prenatal antiseizure medication: A population-based retrospective cohort study.
Article in Epilepsia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Industrial emissions and risks of preterm and small-for-gestational-age birth: A population-based cohort study in Quebec, Canada.Environmental epidemiology (Philadelphia, Pa.) · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
OBJECTIVE(S): Pregnancy in women with epilepsy is associated with adverse perinatal outcomes, but debate remains as to role of epilepsy or of prenatal antiseizure medication (ASM), or both. We aimed to investigate the association between maternal epilepsy and perinatal outcomes, and to explore the role of prenatal ASM exposure.
methodsRetrospective population-based cohort study using linked routinely-collected health data (Scotland, 2009-2021). We included women with at least one singleton pregnancy. Our exposures included (1) maternal epilepsy, identified using International Classification of Diseases, Tenth Revision codes; (2) prenatal ASM, defined as dispensed within the prenatal period. We conducted multi-level multiple regressions accounting for covariates and multiple pregnancies comparing: (1) women with (WWE) and without epilepsy (WWoE), (2) all pregnancies exposed and unexposed to prenatal ASMs, and (3) individual prenatal ASM monotherapy vs without ASM.
resultsA total of 629 200 pregnancies occurred from 2009-2021 (WWE = 2022, WWoE = 627 178; with ASM = 4406, without ASM = 624 794). WWE had increased odds of preterm birth, induced labor, cesarean section, preeclampsia, neonatal intensive care unit admission, low birth weight, and 5-min Apgar score <7. In fully adjusted models, only induced labor adjusted odds ratio aOR [95 CI]b 1.17 (95% confidence interval [CI]: 1.02-1.34) remained associated. Compared to women without ASM, those with ASM had increased odds of preterm birth (aOR 1.47, 95% CI: 1.25-1.74), induced labor (1.38, 1.25-1.52), cesarean section (1.14, 1.01-1.27), neonatal congenital conditions (1.34, 1.04-1.73), neonatal intensive care unit admission (1.54, 1.33-1.78), and low birthweight (1.47, 1.23-1.75). Increased odds were also observed for specific ASM monotherapies. SIGNIFICANCE: Maternal epilepsy is associated with many adverse perinatal outcomes, but most are driven by prenatal ASM exposure. We postulate that joint comprehensive care between obstetricians and epileptologists or other specialists who prescribe ASMs could improve perinatal outcomes. Research into models of care and prescribers and the effect on outcomes is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.